Bradbury N, Wilson L F, Mulholland R C
Harlow Wood Orthopaedic Hospital, Mansfield, United Kingdom.
Spine (Phila Pa 1976). 1996 Feb 1;21(3):372-7. doi: 10.1097/00007632-199602010-00024.
This study compared chymopapain with primary surgery in the treatment of 60 radiologically proven adolescent lumbar disc protrusions and symptoms of low back pain and sciatica; the failures of intradiscal therapy were treated by surgical discectomy.
To establish whether chymopapain is as good as primary surgery in treating adolescents with proven lumbar disc protrusions.
Symptomatic lumbar disc protrusions are rare in white adolescents; the reported incidence varies from 0.8% to 3.2% of all lumbar disc protrusions. This is the largest study with long-term follow-up in the world literature.
Forty-two patients between the ages of 13 and 19 years with proven lumbar disc protrusions were initially treated with chymopapain; the failures of intradiscal therapy were treated by surgical discectomy. Eighteen patients were treated with surgical discectomy. After initial review at 1, 3, 6, and 12 months, the patients were assessed using a postal questionnaire and telephone interview at a minimum of 5 years' follow-up (means: 8.5 years for chymopapain group, 7.2 years for surgery group).
Full replies were received from 16 of 18 (89%) in the surgery group and 42 of 42 (100%) in the chymopapain group. The long-term outcome is classed as good or excellent in 81% of the surgical group and 64% in the chymopapain group. If chymopapain is used as a first-line treatment, with surgery reserved for the failures, the long-term outcome is good or excellent in 82%. The chymopapain group had a shorter hospital stay. The surgical group were more likely to be unemployed and were less able to perform manual work and less able to engage in sporting activity.
Back pain, radicular pain, and tension signs are common, but neurologic signs are less frequent in this age group. Long-term results of surgery are no better than the results of first-line chymopapain treatment with surgery being reserved for the failures. In 60% to 70% of patients, the morbidity, cost, and hospital stay were lessened. The patient is more likely to be in satisfactory employment after chemonucleolysis than after primary surgery.
本研究比较了木瓜凝乳蛋白酶与初次手术治疗60例经影像学证实的青少年腰椎间盘突出症及腰痛和坐骨神经痛症状的效果;椎间盘内治疗失败的患者接受手术椎间盘切除术。
确定木瓜凝乳蛋白酶在治疗已证实的青少年腰椎间盘突出症方面是否与初次手术效果相当。
有症状的腰椎间盘突出症在白人青少年中很少见;报告的发病率占所有腰椎间盘突出症的0.8%至3.2%。这是世界文献中最大的一项长期随访研究。
42例年龄在13至19岁、经证实患有腰椎间盘突出症的患者最初接受木瓜凝乳蛋白酶治疗;椎间盘内治疗失败的患者接受手术椎间盘切除术。18例患者接受手术椎间盘切除术。在1、3、6和12个月进行初次复查后,通过邮寄问卷和电话访谈对患者进行评估,随访时间至少为5年(平均:木瓜凝乳蛋白酶组为8.5年;手术组为7.2年)。
手术组18例中有16例(89%)、木瓜凝乳蛋白酶组42例中有42例(100%)给出了完整回复。手术组81%、木瓜凝乳蛋白酶组64%的长期结果被评为良好或优秀。如果将木瓜凝乳蛋白酶用作一线治疗,手术仅用于治疗失败的患者,长期结果良好或优秀的比例为82%。木瓜凝乳蛋白酶组住院时间较短。手术组患者更有可能失业,从事体力劳动的能力更弱,参与体育活动的能力也更弱。
背痛、神经根性疼痛和紧张体征很常见,但该年龄组的神经体征较少见。手术的长期效果并不优于一线木瓜凝乳蛋白酶治疗,手术仅用于治疗失败的患者。60%至70%的患者发病率、费用和住院时间有所减少。与初次手术后相比,化学髓核溶解术后患者更有可能获得满意的工作。